{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:32:17Z","timestamp":1765233137652,"version":"build-2065373602"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The International Journal of Biochemistry & Cell Biology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.biocel.2021.106028","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T06:43:55Z","timestamp":1624517035000},"page":"106028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target"],"prefix":"10.1016","volume":"137","author":[{"given":"Yeliz","family":"Aka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahriye","family":"Karakas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ufuk","family":"Acikbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8081-1222","authenticated-orcid":false,"given":"Huveyda","family":"Basaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5226-3521","authenticated-orcid":false,"given":"Ozgur","family":"Gul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozgur","family":"Kutuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.biocel.2021.106028_bib0005","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1158\/1535-7163.MCT-14-0845","article-title":"Functional genetic screen identifies increased sensitivity to WEE1 inhibition in cells with defects in fanconi anemia and HR pathways","volume":"14","author":"Aarts","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.biocel.2021.106028_bib0010","first-page":"79","article-title":"The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells","volume":"3","author":"Baev","year":"2014","journal-title":"Leuk. Res. Rep."},{"issue":"636","key":"10.1016\/j.biocel.2021.106028_bib0015","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aay1451","article-title":"High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors","volume":"13","author":"Bhola","year":"2020","journal-title":"Sci. Signal."},{"issue":"1","key":"10.1016\/j.biocel.2021.106028_bib0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41375-019-0485-x","article-title":"Genetic characterization of ABT-199 sensitivity in human AML","volume":"34","author":"Bisaillon","year":"2020","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.biocel.2021.106028_bib0025","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1158\/1078-0432.CCR-11-0650","article-title":"MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells","volume":"17","author":"Bridges","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.biocel.2021.106028_bib0030","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1083\/jcb.200904049","article-title":"MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts","volume":"187","author":"Brunelle","year":"2009","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.biocel.2021.106028_bib0035","first-page":"9","article-title":"PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer","author":"Brunner","year":"2020","journal-title":"Elife"},{"issue":"3","key":"10.1016\/j.biocel.2021.106028_bib0040","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1172\/JCI122622","article-title":"Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis","volume":"129","author":"Bukhari","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.biocel.2021.106028_bib0045","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","article-title":"Venetoclax: first global approval","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.biocel.2021.106028_bib0050","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1128\/MCB.00620-06","article-title":"Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization","volume":"27","author":"Ding","year":"2007","journal-title":"Mol. Cell. Biol."},{"issue":"31","key":"10.1016\/j.biocel.2021.106028_bib0055","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1038\/sj.onc.1207692","article-title":"MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol","volume":"23","author":"Domina","year":"2004","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biocel.2021.106028_bib0060","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1172\/JCI84386","article-title":"Dual modulation of MCL-1 and mTOR determines the response to sunitinib","volume":"127","author":"Elgendy","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.biocel.2021.106028_bib0065","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1158\/1541-7786.MCR-11-0500","article-title":"WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis","volume":"10","author":"Garimella","year":"2012","journal-title":"Mol. Cancer Res."},{"issue":"16","key":"10.1016\/j.biocel.2021.106028_bib0070","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1158\/1078-0432.CCR-17-0520","article-title":"Molecular pathways: targeting the protein kinase Wee1 in cancer","volume":"23","author":"Geenen","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.biocel.2021.106028_bib0075","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/1541-7786.MCR-10-0200","article-title":"A sensitized RNA interference screen identifies a novel role for the PI3K p110gamma isoform in medulloblastoma cell proliferation and chemoresistance","volume":"9","author":"Guerreiro","year":"2011","journal-title":"Mol. Cancer Res."},{"issue":"8","key":"10.1016\/j.biocel.2021.106028_bib0080","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1158\/1535-7163.MCT-13-0025","article-title":"Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy","volume":"12","author":"Guertin","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"22","key":"10.1016\/j.biocel.2021.106028_bib0085","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1158\/1078-0432.CCR-17-1098","article-title":"Synergy of WEE1 and mTOR inhibition in mutant KRAS-driven lung cancers","volume":"23","author":"Hai","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.biocel.2021.106028_bib0090","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/2159-8290.CD-15-0011","article-title":"The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics","volume":"5","author":"Hata","year":"2015","journal-title":"Cancer Discov."},{"issue":"39","key":"10.1016\/j.biocel.2021.106028_bib0095","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1038\/s41388-018-0212-5","article-title":"BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis","volume":"37","author":"Heinicke","year":"2018","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.biocel.2021.106028_bib0100","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1158\/1541-7786.MCR-10-0436","article-title":"High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells","volume":"9","author":"Henderson","year":"2011","journal-title":"Mol. Cancer Res."},{"issue":"11","key":"10.1016\/j.biocel.2021.106028_bib0105","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1158\/1535-7163.MCT-09-0463","article-title":"Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents","volume":"8","author":"Hirai","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.biocel.2021.106028_bib0110","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1158\/0008-5472.CAN-16-2300","article-title":"SFK\/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer","volume":"77","author":"Ichihara","year":"2017","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.biocel.2021.106028_bib0115","first-page":"2844","article-title":"Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells","volume":"6","author":"Jackisch","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.biocel.2021.106028_bib0120","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-16-2653","article-title":"Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4\/6 inhibition in ER-positive breast cancer","volume":"77","author":"Jansen","year":"2017","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.biocel.2021.106028_bib0125","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/leu.2014.1","article-title":"Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199","volume":"28","author":"Khaw","year":"2014","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.biocel.2021.106028_bib0130","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1158\/0008-5472.CAN-08-1418","article-title":"Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737","volume":"68","author":"Kutuk","year":"2008","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.biocel.2021.106028_bib0135","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1158\/1078-0432.CCR-17-2805","article-title":"The combination of the PARP inhibitor olaparib and the WEE1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer","volume":"24","author":"Lallo","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biocel.2021.106028_bib0140","doi-asserted-by":"crossref","first-page":"27696","DOI":"10.1038\/srep27696","article-title":"Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biocel.2021.106028_bib0145","doi-asserted-by":"crossref","first-page":"17012","DOI":"10.1038\/sigtrans.2017.12","article-title":"Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells","volume":"2","author":"Luedtke","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.biocel.2021.106028_bib0150","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.tips.2016.06.006","article-title":"Targeting WEE1 kinase in cancer","volume":"37","author":"Matheson","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.biocel.2021.106028_bib0155","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.molcel.2006.02.009","article-title":"Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1","volume":"21","author":"Maurer","year":"2006","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.biocel.2021.106028_bib0160","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/cdd.2017.183","article-title":"Why do BCL-2 inhibitors work and where should we use them in the clinic?","volume":"25","author":"Montero","year":"2018","journal-title":"Cell Death Differ."},{"issue":"5","key":"10.1016\/j.biocel.2021.106028_bib0165","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cell.2015.01.042","article-title":"Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy","volume":"160","author":"Montero","year":"2015","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.biocel.2021.106028_bib0170","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41419-020-02910-2","article-title":"The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA","volume":"11","author":"Muenchow","year":"2020","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.biocel.2021.106028_bib0175","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030574","article-title":"Targeting mitochondrial apoptosis to overcome treatment resistance in cancer","volume":"12","author":"Ngoi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6059","key":"10.1016\/j.biocel.2021.106028_bib0180","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.1206727","article-title":"Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy","volume":"334","author":"Ni Chonghaile","year":"2011","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.biocel.2021.106028_bib0185","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","article-title":"Binding of released bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells","volume":"22","author":"Niu","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"7042","key":"10.1016\/j.biocel.2021.106028_bib0190","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.biocel.2021.106028_bib0195","doi-asserted-by":"crossref","first-page":"16220","DOI":"10.18632\/oncotarget.8742","article-title":"Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells","volume":"8","author":"Pallis","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.biocel.2021.106028_bib0200","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.biocel.2021.106028_bib0205","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/bjc.2011.242","article-title":"Reduced association of anti-apoptotic protein Mcl-1 with E3 ligase Mule increases the stability of Mcl-1 in breast cancer cells","volume":"105","author":"Pervin","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biocel.2021.106028_bib0210","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1038\/bcj.2015.88","article-title":"Loss in MCL-1 function sensitizes non-Hodgkin\u2019s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)","volume":"5","author":"Phillips","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.biocel.2021.106028_bib0215","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.bcp.2019.04.022","article-title":"Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis","volume":"164","author":"Qi","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.biocel.2021.106028_bib0220","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","article-title":"Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer","volume":"18","author":"Rudin","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.biocel.2021.106028_bib0225","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/sj.embor.7400375","article-title":"Proapoptotic BAX and BAK control multiple initiator caspases","volume":"6","author":"Ruiz-Vela","year":"2005","journal-title":"EMBO Rep."},{"issue":"12","key":"10.1016\/j.biocel.2021.106028_bib0230","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.tcb.2013.08.003","article-title":"Mitochondria: gatekeepers of response to chemotherapy","volume":"23","author":"Sarosiek","year":"2013","journal-title":"Trends Cell Biol."},{"issue":"12","key":"10.1016\/j.biocel.2021.106028_bib0235","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22122045","article-title":"Regulation of G2\/M transition by inhibition of WEE1 and PKMYT1 kinases","volume":"22","author":"Schmidt","year":"2017","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.biocel.2021.106028_bib0240","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ccr.2005.09.006","article-title":"The BAD protein integrates survival signaling by EGFR\/MAPK and PI3K\/Akt kinase pathways in PTEN-deficient tumor cells","volume":"8","author":"She","year":"2005","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.biocel.2021.106028_bib0245","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s10495-012-0799-x","article-title":"Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1\/Noxa axis","volume":"18","author":"Simonin","year":"2013","journal-title":"Apoptosis"},{"issue":"2","key":"10.1016\/j.biocel.2021.106028_bib0250","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"issue":"21","key":"10.1016\/j.biocel.2021.106028_bib0255","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1158\/1078-0432.CCR-15-0279","article-title":"Wee-1 kinase inhibition sensitizes high-risk HPV+ HNSCC to apoptosis accompanied by downregulation of MCl-1 and XIAP antiapoptotic proteins","volume":"21","author":"Tanaka","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biocel.2021.106028_bib0260","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/med.21516","article-title":"Selective targeting of antiapoptotic BCL-2 proteins in cancer","volume":"39","author":"Timucin","year":"2019","journal-title":"Med. Res. Rev."},{"issue":"9","key":"10.1016\/j.biocel.2021.106028_bib0265","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1158\/0008-5472.CAN-16-3242","article-title":"Mcl-1 degradation is required for targeted therapeutics to eradicate colon cancer cells","volume":"77","author":"Tong","year":"2017","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.biocel.2021.106028_bib0270","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biocel.2021.106028_bib0275","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ccr.2013.06.002","article-title":"Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer","volume":"24","author":"Vaillant","year":"2013","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.biocel.2021.106028_bib0280","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/cdd.2008.25","article-title":"A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells","volume":"15","author":"Vogler","year":"2008","journal-title":"Cell Death Differ."},{"issue":"12","key":"10.1016\/j.biocel.2021.106028_bib0285","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1158\/1541-7786.MCR-09-0304","article-title":"Nicotine enhances the antiapoptotic function of Mcl-1 through phosphorylation","volume":"7","author":"Zhao","year":"2009","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.biocel.2021.106028_bib0290","doi-asserted-by":"crossref","first-page":"43517","DOI":"10.1038\/srep43517","article-title":"WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance","volume":"7","author":"Zheng","year":"2017","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.biocel.2021.106028_bib0295","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.cell.2005.06.009","article-title":"Mule\/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis","volume":"121","author":"Zhong","year":"2005","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.biocel.2021.106028_bib0300","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1007\/s10620-018-5253-7","article-title":"BH3 mimetic ABT-199 enhances the sensitivity of gemcitabine in pancreatic cancer in vitro and in vivo","volume":"63","author":"Zhou","year":"2018","journal-title":"Dig. Dis. Sci."}],"container-title":["The International Journal of Biochemistry & Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1357272521001060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1357272521001060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T07:21:08Z","timestamp":1761204068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1357272521001060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":60,"alternative-id":["S1357272521001060"],"URL":"https:\/\/doi.org\/10.1016\/j.biocel.2021.106028","relation":{},"ISSN":["1357-2725"],"issn-type":[{"type":"print","value":"1357-2725"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target","name":"articletitle","label":"Article Title"},{"value":"The International Journal of Biochemistry & Cell Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biocel.2021.106028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106028"}}